Introduction {#s1}
============

Acute metabolic acidosis developing with sepsis, cardiogenic shock, and hemorrhagic shock contributes to the high mortality of these disorders [@pone.0053932-Gunnerson1]. Indeed, the severity of the metabolic acidosis, as reflected by arterial blood pH, has been found in several studies to be an important predictor of clinical outcome i.e., the more severe the acidemia the greater the mortality [@pone.0053932-Gunnerson1], [@pone.0053932-Siesjo1]. The acidosis contributes to an increase in morbidity and mortality by impairing the function of several organ systems, but primarily the cardiovascular system [@pone.0053932-Kraut1]. In this regard, acidosis is associated with depression of cardiac contractility, increased susceptibility to cardiac arrhythmias, and increased pulmonary vascular resistance, with a predisposition to hypotension and decreased tissue perfusion [@pone.0053932-Siesjo1]--[@pone.0053932-Brimioulle1]. In addition to its impact on the cardiovascular system, experimental studies have revealed evidence of suppression of the immune response and stimulation of an inflammatory state [@pone.0053932-Kellum1], [@pone.0053932-Kellum2].

The detrimental effects of metabolic acidosis have been attributed to changes in critical protein functions arising from alterations in extracellular and intracellular pH [@pone.0053932-Webster1]. Therefore, emphasis has been placed on amelioration of the acidosis and acidemia by administration of base. However, base therapy has not resulted in a consistent reduction in mortality [@pone.0053932-Adrogue1]--[@pone.0053932-Forsythe1]. Studies from our laboratory and that of others have established that the intracellular acidosis present with acute metabolic acidosis causes activation of the Na^+^/H^+^ exchanger (NHE1), a ubiquitous plasma-membrane transport system that functions in the regulation of cytoplasmic pH, resulting in deleterious increments in intracellular sodium and calcium and impairment in cardiovascular function [@pone.0053932-Anderson1]--[@pone.0053932-Wu1]. Consistent with this theory are findings that administration of a selective NHE1 inhibitor to animals with hemorrhagic shock or sepsis attenuates the depression in cardiovascular function and leads to a decrease in mortality [@pone.0053932-Wu1], [@pone.0053932-Sikes1]. Using a porcine model of asphyxia-induced cardiac arrest, a model in which hypoxia of tissues and the resultant lactic acidosis is more global, we recently showed that administration of sabiporide, a potent and selective NHE1 inhibitor affords protection from whole body ischemia-reperfusion injury by attenuating myocardial dysfunction, improving organ blood flows and systemic oxygen delivery, resulting in reduced pro-inflammatory response [@pone.0053932-Lin1]. These findings suggest that administration of selective inhibitors of NHE1 lessen the extent of cellular injury, and improve survival. However, in those animal models of hypovolemic circulatory shock, fluid resuscitation results in a normalization of systemic pH. It is not clear whether NHE1 inhibitors can afford protection from severe and persistent systemic metabolic acidosis that seen with critically ill patients. In the present study, we examined the impact of administration of sabiporide on cardiovascular and metabolic function, proinflammatory cytokine production in a model of acute metabolic acidosis produced by hemorrhagic hypotension followed by a lactic acid infusion to produce severe systemic metabolic acidosis [@pone.0053932-Cooper1], [@pone.0053932-Wiklund1]. The results of these studies demonstrate that administration of sabiporide improves cardiovascular and metabolic function, and attenuates proinflammatory cytokine production. Moreover, this treatment reduces mortality, despite having little impact on the severity of the metabolic acidosis. These studies give further support to the possible beneficial effects of administration of NHE1 inhibitors in the treatment of acute metabolic acidosis.

Materials and Methods {#s2}
=====================

Animal Preparation {#s2a}
------------------

All animal studies were approved by the Institutional Animal Care and Use Committee at Mount Sinai Medical Center of Florida and complied with the Animal Welfare Act. Fourteen male Yorkshire pigs (29.4±4.5 kg) were anesthetized with ketamine, 10 mg/kg, i.m., and maintained in a surgical plane of anesthesia with intravenous propofol. A cuffed endotracheal tube was placed through the oropharynx, and ventilation was provided on room air with a volume-controlled ventilator (PB 7200 Ventilatory System, Puritan-Bennett, Carlsbad, CA) set to deliver a tidal volume of 10 ml/kg. The respiratory rate was adjusted to ensure a P~a~CO~2~ from 35--45 mmHg. The left external jugular vein was cannulated for the administration of fluids and drugs. Another catheter was placed into the right femoral artery for the measurement of arterial blood pressure and for blood sampling. An 5.5 F balloon-tipped flow directed thermodilution pulmonary arterial catheter (Opticom™, Abbot Laboratories, Chicago, IL, USA) was inserted via the right jugular vein and floated into the pulmonary artery under direct pressure monitoring for measurements of pulmonary arterial pressure, right atrial pressure, core body temperature and cardiac output. All hemodynamic parameters were continuously recorded with a Powerlab data acquisition system. Arterial and central venous blood gases were measured at various intervals during the experiments using a blood gas analyzer (Rapidlab 855, Bayer Corporation, New York). The cardiac output was determined by thermodilution in triplicate using ice-cold saline. Body temperature was maintained between 37°C to 39°C by means of heating pad.

Experimental Protocol {#s2b}
---------------------

The experimental protocol utilized is depicted in [Figure 1](#pone-0053932-g001){ref-type="fig"}. Following completion of the surgical procedure, the animals were allowed to stabilize for 30 minutes. Hypovolemia was then induced by bleeding the pigs through a femoral artery catheter (30 ml/kg blood removed within 30 minutes). The animals were then randomly assigned to receive either 3 mg/kg sabiporide (in 25 ml saline) or vehicle (saline). Personnel performing the studies were unaware of the assignment of the groups. All animals were given an infusion of lactic acid for 2 hours (1 M lactic acid in saline, 20 ml/kg/h for the first 30 min, 10 ml/kg/h for 90 min), followed by 10 ml/kg of Lactated Ringer's administered for an additional 60 minutes. The animals were monitored throughout the procedure and for an additional 2 hours. At the end of experiments, the animals were humanely euthanized while still under anesthesia with 10 ml of Euthanol, a method that is consistent with the recommendation of the Panel on Euthanasia of the American Veterinary Medical Association.

![Details of the experimental protocol are shown.\
Anesthetized pigs were subjected to hypovolemia (30 ml/kg) for 30 minutes. The animals then received a bolus infusion of NHE1 inhibitor (3 mg/kg, sabiporide) or vehicle, followed by lactic acid infusion for 2 hours. The animals were continuously monitored for additional 3 hours.](pone.0053932.g001){#pone-0053932-g001}

Echocardiography {#s2c}
----------------

Echocardiography was performed with the use of a Hewlett-Packard echocardiographic system SONOS 2000 with a 3.5/2.7 MHz transducer and recorded on VCR tapes. In each animal two-dimensional short-axis view was taken at mid-papillary muscle level to obtain left ventricular (LV) ejection fraction (EF). Linear dimensions were measured from two-dimensionally guided M-mode tracing, and fractional shortening (FS) was obtained. An ECG tracing was recorded simultaneously with the echocardiogram. The measurements were made after the recommendation of the American Society of Echocardiography [@pone.0053932-Sahn1], [@pone.0053932-Schiller1]. Wall motion score index (WMSI) was obtained by the sum of wall motion scores divided the number of visualized segments. In this scoring system, higher scores indicate more severe wall motions abnormalities as: 1 = normal, 2 = hypo kinesis, 3 = akinesis, 4 = dyskinesis, 5 = aneurysm [@pone.0053932-Sahn1]. The measurements were made both on line and off line. All measurements were repeated three times, and the results were averaged.

Biochemical Assay {#s2d}
-----------------

Levels of tumor necrosis factor (TNF)-α, IL-6 were determined by using enzyme immunoassay kits according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA). Plasma Troponin-I levels were measured by using a pig cardiac troponin-I enzyme immunoassay kit (Life Diagnostics, Inc., West Cheater, PA). Plasma levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (Biotron Diagnostics, Hemet, CA), and plasma levels of urea (Bioassay System, Hayward, CA) were determined by using assay kits according to the manufacturer's instructions.

Statistical Analysis {#s2e}
--------------------

All data were reported as means ± SD. Statistical analysis was performed by one way ANOVA and Bonferroni's post comparison test for repeated measures. P values \<0.05 were considered to be statistically significant.

Results {#s3}
=======

Hypovolemia followed by lactic acid infusion led to the early death of 3 of the 8 control animals (38%). These three animals were died due to ventricular fibrillation-induced sudden cardiac arrest. In contrast, all of the six animals given the sabiporide survived the experimental protocol ([Fig. 2](#pone-0053932-g002){ref-type="fig"}).

![Survival of animals.\
Three of the eight control animals died either during infusion of lactic acid or after its discontinuation. By contrast, all six animals given sabiporide survived. \*P = 0.0002 vs. the control group by chi square analysis for trend. BL: at baseline; H30: at 30 min of hemorrhage; T30 min, --T300 min: at 30 min, --and 300 min from lactic acid infusion.](pone.0053932.g002){#pone-0053932-g002}

Acid-base Parameters {#s3a}
--------------------

Acid-base parameters in controls and animals given sabiporide are shown in [Table 1](#pone-0053932-t001){ref-type="table"}. Baseline arterial blood pH, 7.47±.02 and arterial blood \[HCO~3~ ^−^\], 24±0.8 mEq/l in controls were not different from that in animals given sabiporide 7.48±.02 and 25±0.5 mEq/l, respectively. Hypotension followed by infusion of lactic acid caused plasma bicarbonate to fall by approximately 16 mEq/l in both groups, and resulting in a blood pH which averaged 6.85±0.05 and 6.87±0.06 in controls and animals given sabiporide, respectively.

10.1371/journal.pone.0053932.t001

###### Changes in acid-base parameters and blood oxygenation after hypovolemia and lactic acidosis.

![](pone.0053932.t001){#pone-0053932-t001-1}

  Parameters                    Groups        BL                       H30 min                                     T30 min                                      T60 min                                                      T120 min                                                                     T180 min                                                                     T240 min                                                                     T300 min
  -------------------------- ------------ ----------- ------------------------------------------ -------------------------------------------- -------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------
  **Arterial pH**              control     7.47±0.02                  7.46±0.01                   6.85±0.05[\#](#nt103){ref-type="table-fn"}   6.98±0.03[\#](#nt103){ref-type="table-fn"}                   6.92±0.03[\#](#nt103){ref-type="table-fn"}                                   7.23±0.06[\#](#nt103){ref-type="table-fn"}                                                   7.39±0.03                                                                    7.45±0.06
                              sabiporide   7.48±0.02                  7.48±0.03                   6.87±0.06[\#](#nt103){ref-type="table-fn"}   7.00±0.06[\#](#nt103){ref-type="table-fn"}                   6.97±0.07[\#](#nt103){ref-type="table-fn"}                                   7.27±0.06[\#](#nt103){ref-type="table-fn"}                                   7.33±0.08[\#](#nt103){ref-type="table-fn"}                                                   7.38±0.06
  **Arterial pCO2**            control     34.1±1.4                    35.2±1.3                   51.8±5.5[\#](#nt103){ref-type="table-fn"}    41.1±1.1[\#](#nt103){ref-type="table-fn"}                    42.8±4.0[\#](#nt103){ref-type="table-fn"}                                                     30.0±4.1                                                                     33.9±2.4                                                                     31.8±4.7
  (mmHg)                      sabiporide   34.7±1.4                    35.4±2.1                   49.4±2.8[\#](#nt103){ref-type="table-fn"}    41.2±3.3[\#](#nt103){ref-type="table-fn"}                    39.6±1.7[\#](#nt103){ref-type="table-fn"}                                                     34.1±1.7                                                                     36.6±1.7                                                                     36.3±1.0
  **Arterial pO2**             control       107±4                      102±6                                       107±8                                        104±6                                        92±12[\#](#nt103){ref-type="table-fn"}                                                        95±5                                                                         99±3                                                                        101±5
  (mmHg)                      sabiporide     106±8                      105±8                                       104±5                                        112±9                                                         98±9                                                                        104±5                                                                         94±8                                                                         94±7
  **Arterial bicarbonate**     control     24.1±0.8                    24.3±0.5                    8.8±0.8[\#](#nt103){ref-type="table-fn"}     9.5±0.6[\#](#nt103){ref-type="table-fn"}                     8.5±0.4[\#](#nt103){ref-type="table-fn"}                                    13.1±2.8[\#](#nt103){ref-type="table-fn"}                                    20.1±0.2[\#](#nt103){ref-type="table-fn"}                                    21.4±0.9[\#](#nt103){ref-type="table-fn"}
  (mM/L)                      sabiporide   25.4±0.5                    25.6±0.3                    9.0±1.0[\#](#nt103){ref-type="table-fn"}    10.2±1.3[\#](#nt103){ref-type="table-fn"}                     9.1±1.1[\#](#nt103){ref-type="table-fn"}                                    15.7±2.5[\#](#nt103){ref-type="table-fn"}                                    19.4±2.5[\#](#nt103){ref-type="table-fn"}                                    21.5±2.6[\#](#nt103){ref-type="table-fn"}
  **ctHb**                     control     10.1±0.4                    9.7±0.3                     8.1±0.2[\#](#nt103){ref-type="table-fn"}     7.2±0.1[\#](#nt103){ref-type="table-fn"}                     6.9±0.2[\#](#nt103){ref-type="table-fn"}                                     6.7±0.3[\#](#nt103){ref-type="table-fn"}                                     7.1±0.5[\#](#nt103){ref-type="table-fn"}                                     6.9±0.4[\#](#nt103){ref-type="table-fn"}
  (g/dL)                      sabiporide    9.8±0.2                    9.9±0.1                     7.9±0.6[\#](#nt103){ref-type="table-fn"}     7.6±0.4[\#](#nt103){ref-type="table-fn"}                     7.4±0.4[\#](#nt103){ref-type="table-fn"}                                     6.7±0.6[\#](#nt103){ref-type="table-fn"}                                     7.6±0.2[\#](#nt103){ref-type="table-fn"}                                     7.5±0.1[\#](#nt103){ref-type="table-fn"}
  **Hematocrit**               control     29.6±1.1                    29.0±0.9                   24.0±0.4[\#](#nt103){ref-type="table-fn"}    21.0±0.4[\#](#nt103){ref-type="table-fn"}                    20.3±0.8[\#](#nt103){ref-type="table-fn"}                                    19.5±0.6[\#](#nt103){ref-type="table-fn"}                                    21.0±1.2[\#](#nt103){ref-type="table-fn"}                                    20.0±1.0[\#](#nt103){ref-type="table-fn"}
  (%)                         sabiporide   28.8±0.6                    29.5±0.3                   23.3±1.7[\#](#nt103){ref-type="table-fn"}    22.3±1.3[\#](#nt103){ref-type="table-fn"}                    21.8±1.1[\#](#nt103){ref-type="table-fn"}                                    19.5±1.7[\#](#nt103){ref-type="table-fn"}                                    22.3±0.6[\#](#nt103){ref-type="table-fn"}                                    22.0±0.8[\#](#nt103){ref-type="table-fn"}
  **Arterial O2 content**      control     14.1±0.5                    13.6±0.4                   10.5±0.4[\#](#nt103){ref-type="table-fn"}     9.6±0.1[\#](#nt103){ref-type="table-fn"}                     8.4±0.8[\#](#nt103){ref-type="table-fn"}                                     8.9±0.5[\#](#nt103){ref-type="table-fn"}                                     9.7±0.6[\#](#nt103){ref-type="table-fn"}                                     9.6±0.5[\#](#nt103){ref-type="table-fn"}
  (ml/dL)                     sabiporide   13.3±0.5                    13.3±0.8                   10.6±0.8[\#](#nt103){ref-type="table-fn"}    10.1±0.5[\#](#nt103){ref-type="table-fn"}    9.6±0.8[\#](#nt103){ref-type="table-fn"} [\*](#nt102){ref-type="table-fn"}                    9.2±0.7[\#](#nt103){ref-type="table-fn"}                                    10.0±0.6[\#](#nt103){ref-type="table-fn"}                                     9.7±0.6[\#](#nt103){ref-type="table-fn"}
  **Mix-V O2 content**         control      9.6±0.4    4.9±0.1[\#](#nt103){ref-type="table-fn"}    5.9±0.2[\#](#nt103){ref-type="table-fn"}     5.4±0.2[\#](#nt103){ref-type="table-fn"}                     3.2±0.6[\#](#nt103){ref-type="table-fn"}                                     3.3±0.5[\#](#nt103){ref-type="table-fn"}                                     3.4±0.4[\#](#nt103){ref-type="table-fn"}                                     3.2±0.4[\#](#nt103){ref-type="table-fn"}
  (ml/dL)                     sabiporide    9.1±0.6    5.2±1.2[\#](#nt103){ref-type="table-fn"}    6.2±0.9[\#](#nt103){ref-type="table-fn"}     5.7±0.4[\#](#nt103){ref-type="table-fn"}    5.4±0.6[\#](#nt103){ref-type="table-fn"} [\*](#nt102){ref-type="table-fn"}   4.5±0.7[\#](#nt103){ref-type="table-fn"} [\*](#nt102){ref-type="table-fn"}   4.6±0.7[\#](#nt103){ref-type="table-fn"} [\*](#nt102){ref-type="table-fn"}   4.6±0.4[\#](#nt103){ref-type="table-fn"} [\*](#nt102){ref-type="table-fn"}
  **Oxygen consumption**       control      4.4±0.3    3.3±0.3[\#](#nt103){ref-type="table-fn"}                    4.6±0.5                                      4.8±0.5                                                      4.9±0.4                                                                      5.4±0.5                                                                      5.0±0.4                                                                      4.4±0.2
  (ml/kg/min)                 sabiporide    4.5±0.5    3.2±0.6[\#](#nt103){ref-type="table-fn"}                    4.1±0.3                      3.9±0.3[\*](#nt102){ref-type="table-fn"}                                     4.8±0.9                                                                      5.0±0.2                                     6.1±0.4[\#](#nt103){ref-type="table-fn"} [\*](#nt102){ref-type="table-fn"}   5.6±0.5[\#](#nt103){ref-type="table-fn"} [\*](#nt102){ref-type="table-fn"}

All values are expressed as the mean ± SD (n = 5--6).

p\<0.05 vs. the control group;

p\<0.05 vs. the baseline value. BL: baseline; H30: at 30 minutes of hypovolemia; T30 min, --T300 min: at 30 min, --and 300 min from lactic acid infusion.

Effects of Sabiporide on Hemodynamic Parameters and Cardiac Function {#s3b}
--------------------------------------------------------------------

Hemorrhage alone resulted in severe depression of cardiac index and a fall in blood pressure in both groups ([Table 2](#pone-0053932-t002){ref-type="table"}): Cardiac output decreased by approximately 61%, and mean arterial blood pressure (MAP) decreased by approximately 65% in both groups within the first 30 min following hemorrhage. The subsequent infusion of lactic acid to controls caused an increase in pulmonary artery pressure (PAP, ↑ by 205%), pulmonary vascular resistance (PVR, ↑ by 746%), and right atrial pressure (RAP, ↑ by 232%). There was an initial improvement in arterial blood pressure and cardiac output, presumably due, in part, to volume expansion caused by the fluid administration. However, the cardiac output subsequently decreased reaching values significantly below baseline. In the group receiving sabiporide, the infusion of lactic acid also caused an initial rise in cardiac output. However, in contrast to the control group, sabopiride administration caused cardiac output to remain elevated at values that were significantly higher than control and close to baseline. Moreover, the increments in pulmonary arterial pressure, pulmonary vascular resistance and right atrial pressure observed in the control group were considerably dampened, resulting in a reduced preload and improved cardiac output ([Figure 3](#pone-0053932-g003){ref-type="fig"}).

![Changes in pulmonary arterial pressure and pulmonary vascular resistance.\
Pulmonary arterial pressure and vascular resistance rose in controls with lactic acid infusions and remained elevated throughout the study. The increase in both parameters was blunted with sabiporide. All values are the mean ± SD. N = 5--6. \*p\<0.05 vs. the control group; \#p\<0.05 vs. the baseline value.](pone.0053932.g003){#pone-0053932-g003}

10.1371/journal.pone.0053932.t002

###### Changes in hemodynamics after hypovolemia and lactic acidosis in pigs.

![](pone.0053932.t002){#pone-0053932-t002-2}

  Parameters                              Groups          BL                      H30 min                                                   T30 min                                                     T60 min                                    T120 min                                    T180 min                                    T240 min                                    T300 min
  ---------------------------------- ---------------- ---------- ----------------------------------------- -------------------------------------------------------------------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- -------------------------------------------
  **Arterial blood pressure**          **control**       87±5      30±2[\#](#nt106){ref-type="table-fn"}                                      84±5                                                       101±7                                      106±15                                      110±11                                      110±17                                      105±19
  **(mmHg)**                          **sabiporide**     90±6      33±1[\#](#nt106){ref-type="table-fn"}    103±4[\#](#nt106){ref-type="table-fn"} [\*](#nt105){ref-type="table-fn"}    110±5[\#](#nt106){ref-type="table-fn"}      116±3[\#](#nt106){ref-type="table-fn"}      106±6[\#](#nt106){ref-type="table-fn"}      111±9[\#](#nt106){ref-type="table-fn"}                       99±9
  **Heart rate**                       **control**       66±5     125±12[\#](#nt106){ref-type="table-fn"}                                    97±11                                                       99±12                      120±26[\#](#nt106){ref-type="table-fn"}                     107±28                                      110±13                      122±20[\#](#nt106){ref-type="table-fn"}
  **(beats/min)**                     **sabiporide**     70±5     141±13[\#](#nt106){ref-type="table-fn"}                                     95±9                                      110±10[\#](#nt106){ref-type="table-fn"}     114±10[\#](#nt106){ref-type="table-fn"}     115±19[\#](#nt106){ref-type="table-fn"}     115±13[\#](#nt106){ref-type="table-fn"}     123±10[\#](#nt106){ref-type="table-fn"}
  **Right atrial pressure**            **control**     8.1±0.8                    4.9±0.5                                  19.5±1.8[\#](#nt106){ref-type="table-fn"}                   24.5±3.4[\#](#nt106){ref-type="table-fn"}   24.4±5.6[\#](#nt106){ref-type="table-fn"}   16.4±3.6[\#](#nt106){ref-type="table-fn"}   17.5±3.5[\#](#nt106){ref-type="table-fn"}   16.9±3.4[\#](#nt106){ref-type="table-fn"}
  **(mmHg)**                          **sabiporide**   10.2±1.0                   6.1±0.7                                  21.6±3.9[\#](#nt106){ref-type="table-fn"}                   23.2±5.7[\#](#nt106){ref-type="table-fn"}   24.2±4.2[\#](#nt106){ref-type="table-fn"}                   15.8±2.0                    12.9±1.6[\*](#nt105){ref-type="table-fn"}   12.0±1.5[\*](#nt105){ref-type="table-fn"}
  **Systemic vascular resistance**     **control**       65±5      43±5[\#](#nt106){ref-type="table-fn"}                                      58±7                                                       57±10                                       66±15                                       87±20                                       94±19                      98±21[\#](#nt106){ref-type="table-fn"}
  **(mmHg mL^−1^ kg^−1^ min^−1^)**    **sabiporide**     59±4      40±7[\#](#nt106){ref-type="table-fn"}                     76±14[\*](#nt105){ref-type="table-fn"}                      81±3[\*](#nt105){ref-type="table-fn"}                       74±8                       85±11[\#](#nt106){ref-type="table-fn"}      83±14[\#](#nt106){ref-type="table-fn"}      74±14[\*](#nt105){ref-type="table-fn"}
  **Coronary perfusion pressure**      **control**       79±4      23±2[\#](#nt106){ref-type="table-fn"}                                      70±6                                                       76±7                                        81±18                                       94±14                                       92±19                                       88±20
  **(mmHg)**                          **sabiporide**     79±7      25±1[\#](#nt106){ref-type="table-fn"}                                      82±3                                                       87±3                                        91±5                        97±9[\#](#nt106){ref-type="table-fn"}      96±13[\#](#nt106){ref-type="table-fn"}                       87±9
  **Cardiac output/body weight**       **control**       98±5      38±4[\#](#nt106){ref-type="table-fn"}                                     103±17                                                     116±18                                       98±7                                        89±9                                        79±2                                        71±3
  **(mL^−1^ kg^−1^ min^−1^)**         **sabiporide**    105±6     43±14[\#](#nt106){ref-type="table-fn"}                     93±15[\#](#nt106){ref-type="table-fn"}                      95±5[\*](#nt105){ref-type="table-fn"}                       106±9                                      103±13                      106±8[\*](#nt105){ref-type="table-fn"}      107±15[\*](#nt105){ref-type="table-fn"}

All values are the mean ± SD (n = 5--6).

p\<0.05 vs. the control group;

p\<0.05 vs. the baseline value. BL: baseline; H30: at 30 minutes of hypovolemia; T30 min, --T300 min: at 30 min, --and 300 min from lactic acid infusion.

Echocardiographic measurement shows that hypovolemia followed by a lactic acid infusion reduced left ventricular ejection fraction, decreased fractional shortening, and impaired wall motion ([Table 3](#pone-0053932-t003){ref-type="table"}). In contrast, in animals given sabiporide left ventricular ejection fraction and fractional shortening were higher and wall motion was improved compared to vehicle control animals.

10.1371/journal.pone.0053932.t003

###### Echocardiographic measurements of left ventricular ejection fraction, fractional shortening and wall motion score index.

![](pone.0053932.t003){#pone-0053932-t003-3}

                                      BL                       H30 min                                                     T120 min                                                                      T180 min                                                                      T300 min
  ------------------------------- ---------- ------------------------------------------- ----------------------------------------------------------------------------- ----------------------------------------------------------------------------- -----------------------------------------------------------------------------
  **Ejection fraction (%)**                                                                                                                                                                                                                          
  Control                          60.2±4.4   45.5±5.1[\#](#nt109){ref-type="table-fn"}                    35.4±3.9[\#](#nt109){ref-type="table-fn"}                                     34.9±4.3[\#](#nt109){ref-type="table-fn"}                                     31.2±3.6[\#](#nt109){ref-type="table-fn"}
  sabiporide                       58.7±4.5   43.8±3.9[\#](#nt109){ref-type="table-fn"}   46.2±4.1[\#](#nt109){ref-type="table-fn"} [\*](#nt108){ref-type="table-fn"}   48.2±4.1[\#](#nt109){ref-type="table-fn"} [\*](#nt108){ref-type="table-fn"}   42.7±3.7[\#](#nt109){ref-type="table-fn"} [\*](#nt108){ref-type="table-fn"}
  **Fractional shortening (%)**                                                                                                                                                                                                                      
  Control                          31.7±2.6   24.3±2.1[\#](#nt109){ref-type="table-fn"}                    15.3±2.5[\#](#nt109){ref-type="table-fn"}                                     15.6±2.7[\#](#nt109){ref-type="table-fn"}                                     11.8±2.4[\#](#nt109){ref-type="table-fn"}
  sabiporide                       32.5±3.0   25.4±3.9[\#](#nt109){ref-type="table-fn"}   21.6±3.1[\#](#nt109){ref-type="table-fn"} [\*](#nt108){ref-type="table-fn"}   23.3±2.9[\#](#nt109){ref-type="table-fn"} [\*](#nt108){ref-type="table-fn"}   20.4±2.8[\#](#nt109){ref-type="table-fn"} [\*](#nt108){ref-type="table-fn"}
  **Wall Motion Score Index**                                                                                                                                                                                                                        
  Control                          1.0±0.0                    1.2±0.10                                     2.2±0.19[\#](#nt109){ref-type="table-fn"}                                     2.5±0.17[\#](#nt109){ref-type="table-fn"}                                     2.6±0.21[\#](#nt109){ref-type="table-fn"}
  sabiporide                       1.0±0.0                    1.2±0.11                    1.5±0.17[\#](#nt109){ref-type="table-fn"} [\*](#nt108){ref-type="table-fn"}   1.7±0.13[\#](#nt109){ref-type="table-fn"} [\*](#nt108){ref-type="table-fn"}   1.8±0.15[\#](#nt109){ref-type="table-fn"} [\*](#nt108){ref-type="table-fn"}

All values are the mean ± SD (n = 5--6).

p\<0.05 vs. the control group;

p\<0.05 vs. the baseline value. BL: baseline; H30 min: end of hypovolemia; T120 min: end of lactic acid infusion; T180 min: end of fluid infusion; and T300 min: end of the experiment.

Effects of Sabiporide on Blood Oxygenation {#s3c}
------------------------------------------

As indicated in [Table 1](#pone-0053932-t001){ref-type="table"} and [Figures 4A--D](#pone-0053932-g004){ref-type="fig"}, there was a marked decrease in mixed venous blood oxygen saturation and oxygen content, associated with a marked increase in tissue oxygen extraction following hypovolemia in controls. There was no significant difference between two study groups. There was a temporary increase in mixed venous blood oxygen saturation and oxygenated hemoglobin ratio immediately after lactic acid infusion followed by sustained decrease throughout the experiment. Lactic acid infusion caused an initial return in oxygen delivery, but then followed by a decrease. Oxygen delivery continued to fall even after the acid infusion was terminated in control animals. Oxygen consumption in controls was increased during the acid infusion and remained above baseline level throughout the experiment (no significant difference vs. the baseline). Thus, in control animals, the imbalance between oxygen delivery and oxygen consumption resulted in increased oxygen extraction ratio. Oxygen extraction ratio reached 74% after lactic acid infusion, and remained high throughout the experiment, indicating low tissue oxygenation in control animals.

![Changes in mixed-venous blood oxygen saturation, oxygen delivery, oxygen extraction ratio and mixed-venous blood oxygenated hemoglobin/total Hb ratio (FO~2~Hb) ratio.\
NHE1 inhibition with sabiporide prevented excessive fall in mixed-venous blood oxygen saturation following hypovolemia and lactic acidosis, and improved mixed-venous blood oxygen binding capacity of hemoglobin, resulting in improved oxygen delivery and decreased oxygen extraction ratio, suggesting improved tissue oxygenation. All values are the mean ± SD. N = 5--6. \*p\<0.05 vs. the control group; \#p\<0.05 vs. the baseline value.](pone.0053932.g004){#pone-0053932-g004}

In contrast, in animals received sabiporide, the oxygen consumption did not increase to the same extend as in the control animals at the beginning of the acid infusion, but gradually increased reaching values 32% greater than the control group at the end of the experimental period. Sabiporide prevented the excessive fall in mixed-venous oxygen saturation and oxygen binding capacity of hemoglobin, resulting in improved oxygen delivery and decreased oxygen extraction ratio, consistent with improved tissue oxygenation.

Effects of Sabiporide on Inflammatory Response and Indices of Organ Injury {#s3d}
--------------------------------------------------------------------------

The hypotension and infusion of lactic acid resulted in a significant increase in proinflammatory cytokine production in controls ([Table 4](#pone-0053932-t004){ref-type="table"}). In the animals receiving sabiporide, the increase in TNF-α and IL-6 levels noted in controls were reduced by 50% and 63%, respectively.

10.1371/journal.pone.0053932.t004

###### Changes of plasma levels of TNF-α, IL-6, troponin-I, ALT, AST and urea following severe lactic acidosis in pigs.

![](pone.0053932.t004){#pone-0053932-t004-4}

                                BL        H30 min                                       T120 min                                                                        T300 min
  ------------------------ ------------ ------------ ------------------------------------------------------------------------------- -------------------------------------------------------------------------------
  **TNF-α (pg/ml)**                                                                                                                  
  Control                   170.7±51.1   195.6±56.3                    327.0±75.2[\#](#nt112){ref-type="table-fn"}                                     579.9±93.1[\#](#nt112){ref-type="table-fn"}
  sabiporide                178.2±46.2   201.9±51.2                    210.5±52.3[\*](#nt111){ref-type="table-fn"}                    288.4±32.1[\#](#nt112){ref-type="table-fn"} [\*](#nt111){ref-type="table-fn"}
  **IL-6 (pg/ml)**                                                                                                                   
  Control                    729±146      795±176                       1312±201[\#](#nt112){ref-type="table-fn"}                                       2813±355[\#](#nt112){ref-type="table-fn"}
  sabiporide                 714±128      774±143                                        877±151                                       1037±220[\#](#nt112){ref-type="table-fn"} [\*](#nt111){ref-type="table-fn"}
  **Troponin-I (ng/ml)**                                                                                                             
  Control                   0.23±0.03    0.29±0.08                     7.82±1.21[\#](#nt112){ref-type="table-fn"}                                      97.7±16.2[\#](#nt112){ref-type="table-fn"}
  sabiporide                0.26±0.02    0.27±0.05                     5.31±0.82[\#](#nt112){ref-type="table-fn"}                      45.3±7.9[\#](#nt112){ref-type="table-fn"} [\*](#nt111){ref-type="table-fn"}
  **ALT (U/L)**                                                                                                                      
  Control                    13.7±2.7     15.6±3.4                      30.1±4.9[\#](#nt112){ref-type="table-fn"}                                       48.3±6.2[\#](#nt112){ref-type="table-fn"}
  sabiporide                 14.1±3.9     14.9±3.3                      19.5±3.1[\*](#nt111){ref-type="table-fn"}                      31.7±4.0[\#](#nt112){ref-type="table-fn"} [\*](#nt111){ref-type="table-fn"}
  **AST (U/L)**                                                                                                                      
  Control                   92.3±14.2    101.5±20.2                    204.7±30.1[\#](#nt112){ref-type="table-fn"}                                     327.5±38.8[\#](#nt112){ref-type="table-fn"}
  sabiporide                87.4±16.3    94.1±26.2    137.2±25.9[\#](#nt112){ref-type="table-fn"} [\*](#nt111){ref-type="table-fn"}   211.3±27.5[\#](#nt112){ref-type="table-fn"} [\*](#nt111){ref-type="table-fn"}
  **Urea (mg/dl)**                                                                                                                   
  Control                    57.2±6.5     63.4±8.2                     128.1±21.2[\#](#nt112){ref-type="table-fn"}                                     235.0±30.4[\#](#nt112){ref-type="table-fn"}
  sabiporide                 61.4±7.8     65.9±9.5    89.4±11.8[\#](#nt112){ref-type="table-fn"} [\*](#nt111){ref-type="table-fn"}    140.3±24.8[\#](#nt112){ref-type="table-fn"} [\*](#nt111){ref-type="table-fn"}

All values are the mean ± SD (n = 5--6).

p\<0.05 vs. the control group;

p\<0.05 vs. the baseline value. BL: baseline; H30: at 30 minutes of hypovolemia; T120 min: end of lactic acid infusion; and T300 min: end of the experiment.

Troponin-I levels in plasma were significantly elevated in controls following lactic acid infusion consistent with myocardial damage. The administration of sabiporide led to a 54% reduction in troponin-I levels compared to controls, indicating a reduction in myocardial injury. Similarly, plasma levels of ALT and AST (markers of liver injury) were also significantly increased in controls. However, in animals treated with sabiporide, the increase in ALT level was reduced by 34%, and AST level was reduced by 35% compared to controls. We measured the rise in plasma levels of urea (an indicator of impaired excretory function of the kidney and/or increased catabolism). Plasma levels of urea were significantly increased following severe lactic acidosis, and sabiporide treatment reduced urea levels by 40% compared to control animals.

Discussion {#s4}
==========

Metabolic acidosis is common in seriously ill patients and its presence can have a deleterious impact on clinical outcome [@pone.0053932-Gunnerson1]--[@pone.0053932-Kraut1]. Administration of base, a common therapeutic maneuver does not appreciably improve clinical outcome, even when acidemia is improved [@pone.0053932-Kraut2]. The results of the present study demonstrate that administration of the potent NHE1 selective inhibitor, sabiporide to animals with metabolic acidosis induced by hypoperfusion and a lactic acid infusion, improved cardiac function and the delivery of oxygen, and reduced the excessive increase in pulmonary artery pressure and pulmonary vascular resistance observed in controls. Administration of this NHE1 inhibitor also reduced the proinflammatory cytokine production, lessened the severity of myocardial and liver damage, and reduced mortality.

Several different models have been used experimentally to simulate lactic acidosis in humans. Infusion of lactic acid to produce metabolic acidosis, although it does not duplicate all the cellular changes observed with lactic acidosis observed clinically, it is associated with depression of cardiac contractility [@pone.0053932-Cooper1], [@pone.0053932-Wiklund1]. Therefore, it seems a reasonable model to examine the potential benefits of inhibition of NHE1.

The improvement in cardiovascular function produced by administration of a NHE1 inhibitor is similar to that found in studies of severe hemorrhagic shock reported by our group previously [@pone.0053932-Wu1], [@pone.0053932-Wu2]. It is also consistent with a separate study in rats with sepsis given amiloride at doses designed to block NHE1 [@pone.0053932-Sikes1]. In our recent study in a porcine model of asphyxia-induced cardiac arrest, a model characterized by hypoxia and the resultant global lactic acidosis, we showed that post-arrest administration of sabiporide (3 mg/kg) attenuated cardio-pulmonary dysfunction, improving regional blood flows to vital organs (brain, heart, kidney, liver, spleen, etc.), resulting in reduced pro-inflammatory response [@pone.0053932-Lin1]. In the present study, treatment with sabiporide also attenuated the acidosis-induced excessive increase in pulmonary arterial pressure and pulmonary vascular resistance, improved hemoglobin-oxygen binding capacity, and mixed-venous blood oxygen saturation. The evidence of less myocardial and liver damage is also consistent with improved tissue perfusion resulting from s treatment.

Mortality in patients with metabolic acidosis is increased and with lactic acidosis can reach values of 60 to 80% [@pone.0053932-Kellum3]. Therefore, evidence that therapy can reduce mortality as observed in the present study is important. The reduction in mortality with the NHE1 inhibitor reported in the present study mirrored the reduction in mortality observed by our group in animals subject to severe hemorrhage (50 ml/kg) treated with an NHE1 inhibitor [@pone.0053932-Wu1]. These early deaths were due to myocardial arrhythmias and fibrillation-induced sudden cardiac arrest. NHE1 inhibitors protect from myocardial ischemia-reperfusion induced arrhythmias and fibrillation has been previously reported [@pone.0053932-Anderson1]--[@pone.0053932-Karmazyn1], [@pone.0053932-Wu3]. Our recent studies showed that in a rat model of regional myocardial ischemia-reperfusion injury, sabiporide reduced ischemia-induced ventricular arrhythmias and completed prevented fibrillation-induced early death [@pone.0053932-Doods1]. Thus, it is not surprising that sabiporide prevented arrhythmias and fibrillation-induced early death in the present study.

In addition to impaired cardiovascular function, severe metabolic acidosis has been shown to stimulate an inflammatory state and possibly alter the immune response [@pone.0053932-Kellum1], [@pone.0053932-Kellum3]. In this regard, macrophage production of interleukins is stimulated and lymphocyte function is suppressed with metabolic acidosis, leading to increased inflammation and an impaired immune response [@pone.0053932-Kellum3]. Furthermore, extracellular acidification has been shown to induce human neutrophil activation [@pone.0053932-Martnez1] and acidosis induces CD18 mediated neutrophil--endothelial adhesion and may lead to vascular dysfunction [@pone.0053932-Serrano1]. In previous studies, NHE1 inhibition has been shown to reduce neutrophil accumulation, chemokine production and NF-κB activation, and attenuate leukocyte-endothelial cell interactions, suggesting a possible pathological role of activation of NHE1 in production of tissue inflammatory injury in various experimental settings [@pone.0053932-Forsythe1], [@pone.0053932-Wu2], [@pone.0053932-Nemeth1]. Our recent study in a pig model of traumatic hemorrhagic shock, we also showed NHE1 inhibition inhibits NF-κB activation and neutrophil infiltration, reduces iNOS expression and ERK1/2 phosphorylation, thereby, reducing systemic inflammation and thus multi-organ injury [@pone.0053932-Wu4]. In the present study, hypotension and lactic acid infusion resulted in increased proinflammatory cytokine production, whereas, NHE1 inhibition lessened the production of proinflammatory cytokines TNF-α and IL-6. These findings suggest that activation of NHE1 might mediate the inflammatory response found with acute metabolic acidosis.

Excellent reviews have been published on the pathogenic mechanisms of pH-regulatory NHE1 activation and protective actions of NHE1 inhibitors via attenuation of cellular ionic derangement [@pone.0053932-Anderson1]--[@pone.0053932-Karmazyn1]. The application of these concepts to the settings of systemic metabolic acidosis is novel. Although most studies investigated the protective effects of NHE1 inhibition in cardiac myocytes/heart, the fact is that NHE1 is ubiquitously expressed in all mammalian cells [@pone.0053932-Anderson1]--[@pone.0053932-Karmazyn1]. Thus, our demonstration of whole body protective actions by a potent selective NHE1 inhibitor in a setting of global metabolic acidosis in vivo should lead to a refocus of the therapeutic potential of NHE1 inhibitors: a whole body protection from systemic metabolic acidosis.

Taken as a whole, these studies indicate that treatment with sabiporide can improve cardiovascular performance in organisms with acute metabolic acidosis, lessen the inflammatory response, prevent or lessen tissue injury, and reduce mortality. Given, the lack of effective therapies for the treatment of acute metabolic acidosis, these observations could support the utilization of administration of NHE1 inhibitor as an ancillary measure to efforts designed to improve cardiovascular and metabolic function in patients with acute severe metabolic acidosis.
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